UNH » Topics » Reviews of Stock Option Granting Practices

This excerpt taken from the UNH 10-Q filed May 11, 2006.

Reviews of Stock Option Granting Practices

 

In March 2006, the Company and its board of directors initiated separate internal and independent reviews of the Company’s stock option granting practices from 1994 to the present. The reviews encompass all option grants made under the Company’s various stock option plans in effect during this period.

 

The independent review is being conducted by a committee comprised of independent directors (the Special Committee) with the assistance of independent counsel and accounting advisors. The Company’s internal review is being conducted with the assistance of outside counsel and accounting advisors. These reviews are continuing and neither the Special Committee nor the Company has reached final conclusions.

 

The results of the review to date indicate that the Company may be required to record adjustments to non-cash charges for stock-based compensation expense in periods prior to January 1, 2006, in accordance with Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (APB 25). Any such charges could be material and, in such event, would require restatement of the Company’s historical financial statements prepared in accordance with APB 25.

 

If any such non-cash adjustments were deemed necessary it may also result in compensation related to certain exercised stock options, previously thought to be deductible, to be nondeductible under Section 162(m) of the

 

19


Table of Contents

UNITEDHEALTH GROUP

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 

Internal Revenue Code. In that event the Company may be required to pay additional taxes and interest associated with deductions it previously took for compensation associated with such exercised stock options and the Company may lose additional deductions in future periods. Although the Company currently estimates that the amount of any lost tax deductions related to previously filed income tax returns will not be material to our consolidated results of operations or financial position, the Company will not be able to finalize its assessment of this matter until the Special Committee has completed its review.

 

The Company has not reached a final determination with respect to such matters currently under review. The tables below set forth the Company’s current estimate of the maximum potential impact of the matters under internal review, under the historical APB 25 basis of accounting, on the Company’s financial statements for 2003, 2004 and 2005, in the event all such matters require adjustment to the Company.

 

              Year Ended December 31,         

     2005

   2004

   2003

     (in millions, except share amounts)

Historical APB 25 Basis of Accounting

                    

Currently Estimated Potential Decrease to:

                    

Earnings From Operations

   $ 215    $ 110    $ 68

Net Earnings

   $ 150    $ 84    $ 52

Diluted Net Earnings per Common Share

   $ 0.11    $ 0.06    $ 0.04

As a Percentage of:

                    

Earnings From Operations

     4.0%      2.7%      2.3%

Net Earnings

     4.5%      3.2%      2.8%

Diluted Net Earnings per Common Share

     4.4%      3.0%      2.7%

 

The Company does not believe there will be any material impact resulting from the reviews to our results of operations for the three months ended March 31, 2006.

 

The Company believes that the potential impact under the FAS 123R basis of accounting of any adjustments resulting from the reviews are significantly less than the potential impact under the historical APB 25 basis of accounting.

 

20


Table of Contents

UNITEDHEALTH GROUP

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki